Annexon Reports $54.9M Net Loss in Q3 2025, Increases R&D Spending

Annexon, Inc. reported significant financial results for the third quarter of 2025, revealing a net loss of $54.9 million, compared to a net loss of $34.8 million for the same period in 2024, marking a 58% increase in losses year-over-year. For the nine months ending September 30, 2025, the company recorded a net loss of $158.4 million, up from $89.6 million in the prior year, reflecting a 77% increase. Total operating expenses for the third quarter reached $57.0 million, a 45% increase from $39.4 million in the previous year, driven primarily by a 65% rise in research and development expenses, which totaled $49.7 million.

The company's financial position has also changed significantly, with total assets decreasing to $229.1 million as of September 30, 2025, down from $350.1 million at the end of 2024. This decline was largely due to a reduction in cash and short-term investments, which fell from $312.0 million to $188.7 million. The accumulated deficit increased to $869.1 million, reflecting the ongoing investment in research and development activities. Current liabilities rose to $43.6 million, up from $30.5 million at the end of 2024, indicating increased operational costs.

Strategically, Annexon has focused on advancing its clinical pipeline, particularly in neuroinflammatory diseases. The company is progressing with its lead product candidates, including tanruprubart for Guillain-Barré Syndrome and vonaprument for geographic atrophy associated with age-related macular degeneration. The Phase 3 ARCHER II trial for vonaprument has completed enrollment, and the company anticipates reporting topline data in the second half of 2026. Additionally, the company has engaged in regulatory discussions with both the FDA and EMA to facilitate the approval process for its therapies.

Operationally, Annexon has increased its workforce to support its expanding clinical programs, with research and development expenses reflecting higher personnel costs. The company reported a significant increase in clinical and nonclinical outside services costs, which rose by 111% to $17.0 million, primarily due to the ongoing trials for its product candidates. The company also reported a decrease in general and administrative expenses, which fell by 22% to $7.3 million, attributed to cost efficiencies and a reduction in consulting fees.

Looking ahead, Annexon anticipates continued investment in its research and development efforts, with expectations of increased expenses as it advances its product candidates through clinical trials and prepares for potential commercialization. The company projects that its existing cash and cash equivalents will support operations into late first quarter 2027, but acknowledges the need for additional funding to sustain its development programs. Future financing may come from equity offerings or collaborations, and the company is actively exploring these options to ensure the continuation of its clinical initiatives.